Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Set of supportive tools/measures vs. standard care · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Set of supportive tools/measures vs. standard care | BEHAVIORAL | - |
Inclusion Criteria: * Male or female patients \>= 18 years * Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives). * Patients with mild essential hyperten...
Set of supportive tools/measures vs. standard care is used for hypertension. It was studied in a Phase 3 clinical trial as an intervention to support drug adherence in treated hypertensive patients. The trial, known as VALIDATE, enrolled 206 participants and was conducted in Germany and Switzerland.
Set of supportive tools/measures vs. standard care is developed by Novartis AG, which trades under the ticker NVS. The company sponsored the Phase 3 clinical trial for this intervention in hypertension.
Set of supportive tools/measures vs. standard care is in Phase 3 clinical development. The Phase 3 trial, NCT00394823, has been completed. The intervention is investigational and not approved for use outside of clinical research.
Set of supportive tools/measures vs. standard care has one completed Phase 3 trial, NCT00394823, titled VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients. The trial enrolled 206 adults with hypertension in Germany and Switzerland.
Set of supportive tools/measures vs. standard care is not the same as valsartan. The trial combined valsartan with supportive measures, but the intervention being studied is the set of supportive tools or measures compared to standard care, not the drug itself.